University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Targeting neuroinflammation : 3-Monothiopomalidomide a new drug candidate to mitigate traumatic brain injury and neurodegeneration

dc.contributor.authorHsueh, Shih-Chang
dc.contributor.authorParekh, Pathik
dc.contributor.authorBatsaikhan, Buyandelger
dc.contributor.authorVargesson, Neil
dc.contributor.authorTweedie, David
dc.contributor.authorLuo, Weiming
dc.contributor.authorPatel, Chirag N.
dc.contributor.authorLiu, Dong
dc.contributor.authorMcDevitt, Ross A.
dc.contributor.authorBaig, Abdul Mannan
dc.contributor.authorKim, Yu Kyung
dc.contributor.authorKim, Sun
dc.contributor.authorHwang, Inho
dc.contributor.authorKim, Juwan
dc.contributor.authorLee, Mee Youn
dc.contributor.authorCarta, Anna R.
dc.contributor.authorSelman, Warren R.
dc.contributor.authorHoffer, Barry J.
dc.contributor.authorKim, Dong Seok
dc.contributor.authorGreig, Nigel H
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Molecular and Cellular Functionen
dc.date.accessioned2025-06-26T08:26:01Z
dc.date.available2025-06-26T08:26:01Z
dc.date.issued2025
dc.descriptionAll authors thank Dr. Michael T. Scerba (Intramural Research Program, National Institute on Aging, NIH, USA) for quantifying the concentration of 3-MP following its nanoformulation.en
dc.description.statusPeer revieweden
dc.format.extent29
dc.format.extent5315237
dc.identifier304176239
dc.identifier40e50eca-2428-4905-9779-adbd9e141508
dc.identifier40524167
dc.identifier105008234782
dc.identifier.citationHsueh, S-C, Parekh, P, Batsaikhan, B, Vargesson, N, Tweedie, D, Luo, W, Patel, C N, Liu, D, McDevitt, R A, Baig, A M, Kim, Y K, Kim, S, Hwang, I, Kim, J, Lee, M Y, Carta, A R, Selman, W R, Hoffer, B J, Kim, D S & Greig, N H 2025, 'Targeting neuroinflammation : 3-Monothiopomalidomide a new drug candidate to mitigate traumatic brain injury and neurodegeneration', Journal of Biomedical Science, vol. 32, 57. https://doi.org/10.1186/s12929-025-01150-wen
dc.identifier.doi10.1186/s12929-025-01150-w
dc.identifier.issn1423-0127
dc.identifier.otherORCID: /0000-0001-8027-114X/work/186968774
dc.identifier.urihttps://hdl.handle.net/2164/25625
dc.identifier.vol32en
dc.language.isoeng
dc.relation.ispartofJournal of Biomedical Scienceen
dc.subjectSubstantive connection via an eligible employment contracten
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectNeuroinflammationen
dc.subjectImmunomodulatory imide drugs (IMiDs)en
dc.subjectMeurodegenerationen
dc.subjectMicrogliaen
dc.subjectTetratogenicityen
dc.subjectPomalidomideen
dc.subjectcereblonen
dc.subjectSplat like transcription factoren
dc.subjectSALL4en
dc.subjectTraumatic brain injuryen
dc.subjectR Medicine (General)en
dc.subjectSupplementary Dataen
dc.subjectDASen
dc.subject.lccR1en
dc.titleTargeting neuroinflammation : 3-Monothiopomalidomide a new drug candidate to mitigate traumatic brain injury and neurodegenerationen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Hsueh_etal_JBMS_Targeting_Neuroinflammation_3-Monothiopomalidomide_VOR.pdf
Size:
5.07 MB
Format:
Adobe Portable Document Format

Collections